I have been unable to get this link to work so I'll post the short summary:

Zacks Reiterates 'Outperform' Rating for CardioGenics Holdings Inc.
MISSISSAUGA, Ontario, Sept 23, 2010 /PRNewswire via COMTEX/ -- Zacks Equity Research issued an update report on CardioGenics Holdings Inc. (OTC Bulletin Board: CGNH) with a six-month price target of $1.22 per shares and a reiteration of its 'Outperform' rating.

The 24-page report, which references CardioGenics' 10-Q for the period ended July 31, 2010, reviews the company's portable QL Care(TM) Analyzer, initially for emergency room heart attack testing, and its paramagnetic bead supply agreements with Merck-Chimie. The company expects to file for FDA 510K approval of its portable QL Care(TM) Analyzer in 1Q 2011.

The Zacks report details the market potential of the QL Care(TM) Analyzer and the broad range of immunoassay tests it will be capable of performing, as well as the market potential for the company's proprietary paramagnetic beads.

Doc